Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

Omico hits impressive milestone

Posted 6 June 2024 AM

An initiative to match people with advanced or incurable cancers, or earlier diagnoses with poor prognosis, to the best treatment for them has reached an important milestone, potentially doubling the overall survival time of those getting matched.

This month cancer genomics initiative PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) reached a major milestone, with over 5,000 Australians diagnosed with hard-to-treat cancers which have very limited treatment options receiving referrals for free comprehensive genomic profiling of their cancer.

To see the whole article, please login

Popular

Is 2024 the Year of Burnout?
Albo puts hand up for pharma selfie
Why pharma redundancies hurt
Top specialist in Deep Fake scam
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home